George Avgerinos - Fortress Biotech Senior Vice President - Biologics Operations
| FBIOP Preferred Stock | USD 6.37 0.15 2.41% |
President
Dr. George Avgerinos, Ph.D. was appointed as the Senior Vice President Biologics Operations of FORTRESS BIOTECH, INC., with effect from June 4, 2013Dr. Avgerinos joined us from AbbVie Inc., where he was Vice President, HUMIRA Manufacturing Sciences and External Partnerships. In his 22year career at AbbVie, formerly Abbott Laboratories, formerly BASF Bioresearch Corporation, Dr. Avgerinos was responsible for many aspects of biologics development and operations. These included the HUMIRA operations franchise, global biologics process and manufacturing sciences, biologics CMC, manufacturing operations, and thirdparty manufacturing. During his tenure, Dr. Avgerinos led and participated in the development of numerous clinical candidates which included the launch of HUMIRA. He supported expansion of the supply chain to over 9 billion in annual global sales. Dr. Avgerinos efforts on HUMIRA have been recognized with numerous awards, including the prestigious Abbott Chairman award in 2011 since 2013.
| Age | 69 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 781 652 4500 |
| Web | https://www.fortressbiotech.com |
Fortress Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3494) % which means that it has lost $0.3494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4338) %, meaning that it generated substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Hong Liang | Kodiak Sciences | 53 | |
| Hubert MD | Forte Biosciences | 55 | |
Management Performance
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.35 |
Fortress Biotech Pref Leadership Team
Elected by the shareholders, the Fortress Biotech's board of directors comprises two types of representatives: Fortress Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fortress. The board's role is to monitor Fortress Biotech's management team and ensure that shareholders' interests are well served. Fortress Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fortress Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsay Rosenwald, Chairman of the Board and Presidentident, CEO | ||
| Samuel Berry, Gen Sec | ||
| Robyn Hunter, Ex Officer | ||
| Michael Esq, Vice Devel | ||
| Thomas Schaible, Project Disease | ||
| George Avgerinos, Senior Vice President - Biologics Operations | ||
| David Jin, CFO Devel |
Fortress Preferred Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right preferred stock is not an easy task. Is Fortress Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Additional Tools for Fortress Preferred Stock Analysis
When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.